BioLineRX Ltd. · TASE:BLRX

BioLineRX — Investor Presentation (March 2014)

38 slides from BioLineRX's investor presentation, March 2014

  1. Slide 1: Company Presentation

    Slide 1: Company Presentation

    Company Presentation March 2014

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains "forward-looking statements." These statements include words like "may," "expects," "believes," “plans,” “scheduled," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and u

  3. Slide 3: BioLineRx - General

    Slide 3: BioLineRx - General

    BioLineRx - General • Founded in 2003 by Teva and other key players in Israeli Life Sciences industry • Bridge “development gap” for Israeli assets – Leverage carefully selected early-stage technology, primarily at academia level, following proof of concept in animals (at a minimum) – Invest 3-6 yea

  4. Slide 4: BioLineRx's Value Proposition

    Slide 4: BioLineRx's Value Proposition

    BioLineRx’s Value Proposition • Multiple shots on goal • Several meaningful value inflection points in next 12 months • Two assets in pivotal studies during next 12 months • Two pharma assets regulated as devices • Strategic relationships and access to Israeli technology 4

  5. Slide 5: Our Proven Business Model

    Slide 5: Our Proven Business Model

    Our Proven Business Model Identify promising Conduct Feasibility Develop through Partner projects Testing` clinical stages • Strong scientific • Validate results of • Accelerated • Continued clinical basis inventors development development, if • High chance of • Resolve main program needed regulator

  6. Slide 6: Efficient Project Development Infrastructure

    Slide 6: Efficient Project Development Infrastructure

    Efficient Project Development Infrastructure Expert Medical and Project Clinical Team Managers BD In-licensing and Pre-Clinical Out-licensing Team Multiple Projects Chemistry Team (Organic, Analytical, Intellectual Bioanalytical, Property Experts Formulation) Regulatory Affairs Team 6

  7. Slide 7: Main Pipeline Assets

    Slide 7: Main Pipeline Assets

    Main Pipeline Assets PROJECT INDICATION LEAD DEVELOPMENT PROGRAMS BL-8040 BL-7010 AML Stem cell mobilization Celiac disease ADDITIONAL DEVELOPMENT PROGRAMS BL-5010 BL-7040 BL-9010 PROGRAMS PARTNERED OR IN CO-DEVELOPMENT BL-1040 BL-8020 BL-8030 BL-9020 Skin lesions Inflammatory bowel disease Severe a

  8. Slide 8: Lead Development Programs

    Slide 8: Lead Development Programs

    LEAD DEVELOPMENT PROGRAMS 8

  9. Slide 9: BL-8040: Best-in-Class CXCR4 Antagonist for Hematological Cancers

    Slide 9: BL-8040: Best-in-Class CXCR4 Antagonist for Hematological Cancers

    BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF HEMATOLOGICAL CANCERS 9

  10. Slide 10: BL-8040 Highlights

    Slide 10: BL-8040 Highlights

    BL-8040 Highlights • Indications: Acute myeloid leukemia (AML) & other hematological cancers – Orphan designation received from FDA for both AML and stem-cell mobilization • Mode of Action: CXCR4 antagonism – CXCR4 over-expressed in >70% of tumors, and correlates with disease severity. • Status: Pha

  11. Slide 11: AML – Treatment and Unmet Medical Need

    Slide 11: AML – Treatment and Unmet Medical Need

    AML – Treatment and Unmet Medical Need • AML is most common acute leukemia in adults – Over 60,000 new cases recorded worldwide in 2010, growing to 130,000 by 2020 – 14,000 cases of AML diagnosed in the US in 2012 – Majority of AML patients relapse and require repeated treatment cycles • AML has poo

  12. Slide 12: BL-8040 Mechanism Of Action

    Slide 12: BL-8040 Mechanism Of Action

    BL-8040 Mechanism Of Action • Binds CXCR4 with high affinity (1-2 nM) • Maintains extended inhibition of CXCR4 through long receptor occupancy (>24 hours) • Works as inverse agonist of CXCR4 • Induces apoptosis of tumor cells dependent on CXCR4 for survival • Increases sensitivity to anti-cancer age

  13. Slide 13: BL-8040 Superiority to Mozobil

    Slide 13: BL-8040 Superiority to Mozobil

    BL-8040 Superiority to Mozobil Mobilization CXCL12 serum levels BL-8040 12 mg/kg BL-8040 0.11 BL-8040 0.167 Number of Neutrophils Mozobil 3.2 mg/kg BL-8040 0.22 Mozobil 0.11 Mozobil 0.167 Mozobil 0.22 Time post BL-8040/Mozobil injection Time post BL-8040/Mozobil injection Cell Death 13

  14. Slide 14: Other Evidence of BL-8040's Superior Anti-Cancer Effect

    Slide 14: Other Evidence of BL-8040's Superior Anti-Cancer Effect

    Other Evidence of BL-8040’s Superior Anti-Cancer Effect BL-8040 (formerly BKT140) inhibits proliferation of Ramos cells compared with Mozobil (AMD3100) and BMS-936564 (MDX-1338) * * Kuhne MR, Clinical Cancer Research, 2012 14

  15. Slide 15: Summary of BL-8040 vs. Competitors

    Slide 15: Summary of BL-8040 vs. Competitors

    Summary of BL-8040 vs. Competitors BL-8040 Mozobil BMS-936564 (BKT-140) (Plerixafor/AMD3100) (MDX1338) Affinity with CXCR4 1-2 nM 84 nM 5nM MOA Inverse agonist Antagonist (partial agonist) Antagonist Extracellular domains in the Trans-membrane regions in Extracellular domains in the CXCR4 Binding si

  16. Slide 16: Current BL-8040 Phase II Study in AML

    Slide 16: Current BL-8040 Phase II Study in AML

    Current BL-8040 Phase II Study in AML • Study summary – Open-label study under IND carried out at multiple centers in the US and Israel – Relapsed or refractory AML patients (up to 50 patients) • Study design – Dose escalation phase - up to 5 escalating doses (0.5-1.5 mg/kg) – Expansion phase of saf

  17. Slide 17: BL-8040 AML Phase II Study Design

    Slide 17: BL-8040 AML Phase II Study Design

    BL-8040 AML Phase II Study Design Relapse Treatment Follow Up BM biopsy: Day: 1 2 3 4 5 6 7 ------------------------------------------------------------ 30 Screening BL-8040 BL-8040 + Chemotherapy [Cytarabine (ARA-C)] Evaluation of response BM biopsy • Completion of AML study expected end of 2014 /

  18. Slide 18: Partial Results in AML Phase II Study

    Slide 18: Partial Results in AML Phase II Study

    Partial Results in AML Phase II Study • Safe at all doses tested to date (0.5, 0.75 and 1mg/kg) • Substantial mobilization of cancer cells from BM to peripheral blood • Evidence for robust effect of cancer cell death Peripheral blood sample apoptosis assay • Additional information on will be provide

  19. Slide 19: Additional Study Planned in Stem-Cell Mobilization

    Slide 19: Additional Study Planned in Stem-Cell Mobilization

    Additional Study Planned in Stem-Cell Mobilization • Expected to start in H1 2014; results expected in H2 2014 In-vivo results show that BL-8040 has significantly better stem cell mobilization, as compared with G-CSF and Mozobil 4000 BKT140 Mobilization of Progenitors Number of progenitors per 1 ml

  20. Slide 20: BL-7010: Novel Gliadin Binding Polymer for Celiac Disease

    Slide 20: BL-7010: Novel Gliadin Binding Polymer for Celiac Disease

    BL-7010: NOVEL GLIADIN BINDING POLYMER FOR CELIAC DISEASE 20

  21. Slide 21: BL-7010: Polymeric Binder for Celiac Disease

    Slide 21: BL-7010: Polymeric Binder for Celiac Disease

    BL-7010: Polymeric Binder for Celiac Disease • Indication: Celiac disease • Mode of Action: Non-absorbable polymer with high affinity to gliadins (immunogenic peptides contained in gluten) • Status: Phase I/II ongoing • Product Highlights – Prevents pathological damage to small intestine – Non-absor

  22. Slide 22: Celiac Disease – Large Unmet Medical Need

    Slide 22: Celiac Disease – Large Unmet Medical Need

    Celiac Disease – Large Unmet Medical Need • 1% of world’s population suffers from celiac disease – Number underestimated due to lack of awareness/diagnostic tools • Market projected to reach $8 billion by 2019 • No current pharmacological agents approved for celiac – Only treatment option is life-lo

  23. Slide 23: BL-7010 Prevents Formation of Gliadin's Immunogenic Peptides

    Slide 23: BL-7010 Prevents Formation of Gliadin's Immunogenic Peptides

    BL-7010 Prevents Formation of Gliadin’s Immunogenic Peptides Gluten Gluten BL-7010 Copolymer of sodium styrene sulfonate (SS) and 2-hydroxyethyl methacrylate (HEMA) Gliadin Enterocytes BL-7010 demonstrates distinguished specificity towards gliadin Small intestinal damage with loss of absorptive vill

  24. Slide 24: BL-7010 Maintains Normal Structure of GI

    Slide 24: BL-7010 Maintains Normal Structure of GI

    BL-7010 Maintains Normal Structure of GI Model: HLA-DQ8/HCD4 transgenic male mice sensitized to gliadin non-sensitized Gluten-sensitized Gluten-sensitized mice mice mice + BL-7010 Villus-to-crypt ratio 5.96 ± 1.23 2.58 ± 0.43 4.89 ± 1.51 24

  25. Slide 25: BL-7010 Clinical Program Overview

    Slide 25: BL-7010 Clinical Program Overview

    BL-7010 Clinical Program Overview Two studies in celiac disease patients are planned in 2014: • Phase I/II study in celiac patients (ongoing) – Single and repeated ascending dose study – Safety endpoints, no efficacy endpoints – Assessment of systemic exposure – Top-line results expected in mid-2014

  26. Slide 26: Partial Results - Ascending Dose Stage of Phase I/II Study

    Slide 26: Partial Results - Ascending Dose Stage of Phase I/II Study

    Partial Results - Ascending Dose Stage of Phase I/II Study • Single administration, dose escalation part of study completed – Study structure based on alternating group design; each subject receiving 3 different single escalating doses of BL-7010 or placebo – Study remains blinded – Escalation reach

  27. Slide 27: BL-1040: First-in-Class Myocardial Implant

    Slide 27: BL-1040: First-in-Class Myocardial Implant

    BL-1040: FIRST-IN-CLASS MYOCARDIAL IMPLANT FOR PREVENTION OF VENTRICULAR REMODELING FOLLOWING AMI Out-licensed to Bellerophon (f/k/a Ikaria) and being developed as Bioabsorbable Cardiac Matrix (BCM) 27

  28. Slide 28: BL-1040 Highlights

    Slide 28: BL-1040 Highlights

    BL-1040 Highlights • Indication: Cardiac remodeling post-AMI • Mode of Action: Provides support to ischemic tissue during healing • Status: CE Mark registration trial - results expected in 2014 • Device designation (including FDA) • Partnered with Bellerophon BCM (f/k/a Ikaria) – Total deal structur

  29. Slide 29: Unmet Medical Need

    Slide 29: Unmet Medical Need

    Unmet Medical Need Vessel occlusion Tissue damage Successfully treated with PCI and stents No sufficiently effective treatment for myocardial damage 29

  30. Slide 30: How Does BL-1040 Work?

    Slide 30: How Does BL-1040 Work?

    How Does BL-1040 Work? Infarct related artery injection Deposits into infarcted tissue Upon contact with infarcted tissue, turns from liquid into gel Gel-like scaffold provides mechanical support to damaged tissue Transitions to liquid and exits the body within 6 weeks 30

  31. Slide 31: BL-1040 Prevents Structural Changes

    Slide 31: BL-1040 Prevents Structural Changes

    BL-1040 Prevents Structural Changes Porcine AMI model, day 60 Dilated left Normal size ventricle left ventricle Normal LV Thin LV wall wall Untreated BL-1040 31

  32. Slide 32: Promising Results from Pilot Study

    Slide 32: Promising Results from Pilot Study

    Promising Results from Pilot Study • Designated as device by regulatory authorities (including FDA) • Pilot study in Europe – completed January 2010 – 27 patients, safety and preliminary efficacy in patients with primary MI at high risk for LV remodeling • 9 sites: 6 in Germany, 3 in Belgium • Trial

  33. Slide 33: BL-1040 Pivotal Clinical Development Program

    Slide 33: BL-1040 Pivotal Clinical Development Program

    BL-1040 Pivotal Clinical Development Program • Pivotal CE Mark Registration trial progressing at full steam – ~75 sites currently active in nine countries (including 15 sites in US) – Placebo controlled, 306 patients, six-month follow-up – Endpoints: End diastolic volume, QLQ, six-minute walk test –

  34. Slide 34: Corporate

    Slide 34: Corporate

    CORPORATE 34

  35. Slide 35: Financial and Corporate Summary

    Slide 35: Financial and Corporate Summary

    Financial and Corporate Summary • Available cash as of December 31, 2013 - ~$18.2 million − Raised additional gross proceeds of ~$24 million in underwritten secondary offering in March 2014 − Annual burn rate ~$12 million − Cash expected to last through beginning of 2017 • Number of employees – 45 −

  36. Slide 36: Analyst Coverage

    Slide 36: Analyst Coverage

    Analyst Coverage BioLineRx Ltd. is followed by the analysts listed below: Analyst Firm Robert Hazlett Roth Capital Partners, LLC Raghuram Selvaraju Aegis Capital Corp. Robin Davison; Jason Zhang Edison Investment Research Please note that any opinions, estimates or forecasts regarding BioLineRx Ltd.

  37. Slide 37: 2014 Major Milestones

    Slide 37: 2014 Major Milestones

    2014 Major Milestones BL-9020 (Type 1 Diabetes) collaboration with JHL √ BL-7010 (Celiac Disease) phase 1/2 study update* √ BL-5010 (Skin Lesions) pivotal EU study initiation BL-8040 (Stem Cell Mobilization) phase 1 initiation BL-8040 (AML) phase 2 partial results* 2014 BL-7010 (Celiac Disease) phas

  38. Slide 38: Bench1o Bedoideto Patner

    Slide 38: Bench1o Bedoideto Patner

    Bench1o Bedoideto Patner BIOLINEM >< 38

Source: Internet Archive copy of biolinerx.com

More decks from BioLineRX Ltd.

All 37 BioLineRX decks